What is DPP-4 (Dipeptidyl Peptidase-4)?
DPP-4 is a cell-surface enzyme that deactivates incretin hormones (particularly GLP-1 and GIP), thereby regulating glucose-dependent insulin secretion, gastric emptying, and postprandial glucagon levels 1, 2, 1.
Biological Function
DPP-4 functions as both a membrane-anchored protein and a soluble circulating enzyme that cleaves N-terminal dipeptides from polypeptides, specifically those containing position 2 alanine or proline 3. Its primary clinical relevance stems from its role in degrading incretin hormones:
- Degrades GLP-1 (glucagon-like peptide-1) - reducing its glucose-lowering effects
- Degrades GIP (glucose-dependent insulinotropic polypeptide) - diminishing insulin secretion
- Regulates multiple metabolic pathways through enzymatic cleavage of various substrates 4, 5
Clinical Significance in Diabetes
DPP-4 represents a key therapeutic target for type 2 diabetes management. DPP-4 inhibitors work by blocking this enzyme, thereby increasing endogenous GLP-1 levels, which enhances insulin secretion and inhibits glucagon secretion in a glucose-dependent manner 6.
Available DPP-4 Inhibitors
The commercially available agents include sitagliptin, saxagliptin, vildagliptin, linagliptin, and alogliptin 6.
Glycemic Efficacy
DPP-4 inhibitors reduce HbA1c by 0.4% to 0.9% in clinical trials 6. This positions them as moderate-efficacy glucose-lowering agents, less potent than metformin, sulfonylureas, or GLP-1 receptor agonists 7.
Safety Profile
The major advantage of DPP-4 inhibitors is their low hypoglycemia risk when used alone and neutral effect on body weight 6. This makes them particularly suitable for patients where hypoglycemia avoidance is critical.
Important Cardiovascular and Heart Failure Considerations
Critical Safety Concern
Some DPP-4 inhibitors increase the risk of heart failure hospitalization, making them problematic in patients with existing heart failure or high cardiovascular risk 1, 8, 2, 1.
Specifically:
- Saxagliptin increased heart failure hospitalization risk by 27% in the SAVOR-TIMI 53 trial 8
- Alogliptin showed increased heart failure risk in post-hoc analysis of patients without prior heart failure 8, 2, 1
- Sitagliptin showed neutral cardiovascular effects in the TECOS trial 8
Mechanistic Concerns
The vildagliptin VIVIDD trial demonstrated that while ejection fraction remained unchanged, left ventricular diastolic and systolic volumes were significantly higher with DPP-4 inhibitor treatment 8. This suggests potential adverse cardiac remodeling effects.
Renal Dosing Requirements
Most DPP-4 inhibitors require dose reduction in renal dysfunction (sitagliptin, saxagliptin, alogliptin, vildagliptin), with the notable exception of linagliptin, which requires no adjustment in liver or renal insufficiency 6.
Beyond Glucose Control
DPP-4 also functions as an adipokine secreted primarily by visceral adipose tissue, where it can disrupt insulin signaling and promote proinflammatory environments 4. This broader metabolic role explains why elevated circulating DPP-4 levels are associated with various metabolic diseases 4, 5.
Clinical Positioning
DPP-4 inhibitors are considered second-line therapy for type 2 diabetes 9. They should not be used concurrently with GLP-1 receptor agonists as they provide no additional glucose lowering beyond GLP-1 agonists alone 10. Their primary role is in patients requiring moderate glucose lowering who prioritize hypoglycemia avoidance and weight neutrality, but they should be avoided or used cautiously in patients with heart failure or high cardiovascular risk 1, 8, 11, 2, 1.